Braveheart Bio, Inc.
Forbion Growth Opportunities Fund III Cooperatief U.A. purchased 1,680,000 indirectly-held shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($30.24M total) on 2026-08-07.
Forbion Growth Opportunities Fund III Cooperatief U.A. purchased 1,920,000 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($34.56M total) on 2026-08-07.
Rickey James Paul (Chief Financial Officer) purchased 27,777 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($0.50M total) on 2026-08-07.
Over the past 7 days, alphai's AI scored 8 news stories mentioning BRVE (Braveheart Bio, Inc.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.
Recent BRVE coverage spans insider activity and ipo.
In the last 30 days, BRVE insiders filed 8 SEC Form 4 transactions — 8 purchases ($69.4M) and no sales. The most active reporter was Forbion Growth Opportunities Fund III Cooperatief U.A. with 2 filings.
The filing signals insider-style accumulation by a large holder, but it is not a company fundamental update.
The Form 4 discloses a large 10% owner open-market buy, which can be read as bullish conviction but is not a fundamental update by itself.
The filing is a fresh insider buy, but it is not a fundamental catalyst like guidance, trial data, or a deal.
The IPO pricing and size are the primary tradable catalyst, shifting BRVE from private/rumor to public liquidity with new float and expectations.
The filing is a fresh insider buy, but it is not a fundamental catalyst like guidance, trial results, or a deal.
alphai scores every news story that mentions BRVE with an AI model for sentiment and relevance, and aggregates insider trades from Braveheart Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Forbion Growth Opportunities Fund III Cooperatief U.A. purchased 1,680,000 indirectly-held shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($30.24M total) on 2026-08-07.
2 min readForbion Growth Opportunities Fund III Cooperatief U.A. purchased 1,920,000 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($34.56M total) on 2026-08-07.
2 min readRickey James Paul (Chief Financial Officer) purchased 27,777 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($0.50M total) on 2026-08-07.
2 min readBraveheart Bio, Inc. (NASDAQ:BRVE) completed its IPO, selling 24,437,500 shares at $18.00 each, according to a company press release. The offering raised $439.9 million in gross proceeds, including full exercise of an option for 3,187,500 extra shares. Shares began trading on the Nasdaq Global Market under BRVE.
3 min readViehbacher Christopher purchased 83,333 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($1.50M total) on 2026-08-07.
2 min readMalek David I purchased 4,166 shares of Braveheart Bio, Inc. (BRVE) at $18.00 on 2026-08-07.
2 min readAnderson Michele A. (Chief Development Officer) purchased 1,111 shares of Braveheart Bio, Inc. (BRVE) at $18.00 on 2026-08-07.
2 min readMurdoch Travis (CEO and President) purchased 83,333 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($1.50M total) on 2026-08-07.
2 min readLubner David Charles purchased 55,555 shares of Braveheart Bio, Inc. (BRVE) at $18.00 ($1.00M total) on 2026-08-07.
2 min readBraveheart Bio, Inc. (Nasdaq: BRVE) upsized its Nasdaq IPO, selling 24,437,500 shares at $18.00 each, including underwriters’ full option for 3,187,500 shares, for gross proceeds of $439.9 million, per the company. Shares began trading Aug. 6, 2026. The lead candidate is BHB-1893 for hypertrophic cardiomyopathy.
2 min read